Free Trial

Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Lowered by Cantor Fitzgerald

Jasper Therapeutics logo with Medical background

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a report issued on Monday, MarketBeat.com reports.

Other equities research analysts have also issued reports about the company. UBS Group reduced their price objective on Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Oppenheimer cut their price target on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. William Blair reaffirmed a "market perform" rating on shares of Jasper Therapeutics in a research note on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Jasper Therapeutics has an average rating of "Moderate Buy" and an average target price of $29.75.

View Our Latest Report on Jasper Therapeutics

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR traded down $0.03 during midday trading on Monday, hitting $3.53. 355,892 shares of the company's stock traded hands, compared to its average volume of 397,256. The firm has a fifty day moving average of $5.21 and a 200 day moving average of $6.46. Jasper Therapeutics has a 1 year low of $2.27 and a 1 year high of $26.05. The stock has a market capitalization of $52.95 million, a price-to-earnings ratio of -0.67 and a beta of 2.69.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). On average, equities analysts anticipate that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

Several large investors have recently made changes to their positions in the business. Wells Fargo & Company MN boosted its position in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after acquiring an additional 3,828 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Jasper Therapeutics in the 4th quarter worth about $223,000. Acadian Asset Management LLC purchased a new position in shares of Jasper Therapeutics during the first quarter valued at approximately $46,000. Tema Etfs LLC bought a new position in Jasper Therapeutics in the 4th quarter valued at $266,000. Finally, Rhumbline Advisers increased its stake in Jasper Therapeutics by 12.6% in the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock worth $316,000 after buying an additional 1,652 shares during the period. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

Recommended Stories

Analyst Recommendations for Jasper Therapeutics (NASDAQ:JSPR)

Should You Invest $1,000 in Jasper Therapeutics Right Now?

Before you consider Jasper Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.

While Jasper Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines